Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System

Recruiting

• Conditions: Heart Failure; Heart Failure With Preserved Ejection Fraction; Heart Failure NYHA Class IV; Heart Failure With Reduced Ejection Fraction

• Registration Number: NCT04237701
• Lead Sponsor: Yale University

Brief Summary

The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System.

Detailed Description

Electronic Health Records based registries can be an important resource for precision medicine delivery by understanding the population burden of chronic diseases such as heart failure. These registries can allow for a deeper understanding of gaps in guideline recommended therapies among patients who are under the purview of large, integrated Therefore, we have created a live registry within the integrated Yale New Haven Health System-the Yale Heart Failure Registry-that includes all patients with a diagnosis of HF and has detailed information about demographics, comorbidities, laboratories, imaging, medications, and clinical outcomes (including hospital readmissions). The registry is updated daily and can be queried for clinically relevant questions aimed at quality improvement.

Study Timeline

• Study Start: 2019-10-01
• Study First Submitted: 2020-01-17
• Study First Submitted QC: 2020-01-17
• Study First Posted: 2020-01-23
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-25
• Last Update Posted: 2024-01-29
• Primary Completion: 2025-12-30
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40000

Inclusion Criteria

• Seen within the Yale New Haven Health System
• Diagnosis of heart failure

Read More

Exclusion Criteria

• Age<18

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of participants hospitalized for heart failure	10 years	Heart Failure hospitalizations
Doses of therapies that comprise guideline directed medical therapy	10 years	Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.

Trial Locations

Locations (1)

Yale New Haven Health System; 🇺🇸 New Haven, Connecticut, United States